PPARA and Hepatic fibrosis: Thus, using PPAR agonists might offer a way to mitigate liver fibrosis through metabolic modulation and HSC inactivation [175,176]; (5) microRNAs (miRNAs) acting as regulators of HSC activity and ECM expression.